Cointime update: China’s National Medical Products Administration approved the marketing of iminexifor for injection (brand name Funokai), a Class 1 innovative drug developed by Suzhou Sinovent Pharmaceuticals, for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP). The drug is indicated for patients aged 18 and older with infections caused by susceptible Gram-negative bacteria including Klebsiella pneumoniae, Acinetobacter baumannii complex, Pseudomonas aeruginosa, Haemophilus influenzae, Klebsiella aerogenes, Enterobacter cloacae, Escherichia coli and Klebsiella oxytoca.
China NMPA Approves Innovative Antibiotic Iminexifor for Hospital-Acquired Pneumonia
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
13m ago
Polus Executive Warns AI Borrowing Boom Signals Weaker Credit Underwriting
1h ago
Dow Falls 1% as US Stocks Extend Losses
3h ago
Spot gold falls 2.59% to slip below $3,750/oz
5h ago
House Democrats Target Trump Inner Circle in First Oversight Requests
5h ago
US Democrats Plan Data Center Power Reform, Operators May Pay $35B More Over 10 Years
5h ago
Democrats to Probe Trump’s $100B Venezuela Oil Deal